{"id":401816,"date":"2023-12-26T09:13:09","date_gmt":"2023-12-26T14:13:09","guid":{"rendered":"https:\/\/platohealth.ai\/amgen-provides-regulatory-update-on-the-status-of-lumakras-medical-device-news-magazine\/"},"modified":"2023-12-27T06:33:49","modified_gmt":"2023-12-27T11:33:49","slug":"amgen-provides-regulatory-update-on-the-status-of-lumakras-medical-device-news-magazine","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/amgen-provides-regulatory-update-on-the-status-of-lumakras-medical-device-news-magazine\/","title":{"rendered":"Amgen Provides Regulatory Update On The Status Of Lumakras\u00ae ( – Medical Device News Magazine","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

Amgen<\/a> (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company\u2019s supplemental New Drug Application seeking full approval of LUMAKRAS\u00ae<\/sup> (sotorasib).<\/h4>\n

This review, which resulted in a Complete Response Letter, was based on the CodeBreaK 200 trial results for the treatment of adults with previously treated locally advanced or metastatic KRAS<\/i> G12C-mutated non-small cell lung cancer (NSCLC). The FDA also issued a new postmarketing requirement (PMR) for an additional confirmatory study to support full approval that will be completed no later than February 2028<\/span>.<\/p>\n

In addition, the FDA concluded that the dose comparison PMR issued at the time of LUMAKRAS accelerated approval, to compare the safety and efficacy of LUMAKRAS 960 mg daily dose versus a lower daily dose, has been fulfilled. The company said LUMAKRAS at 960 mg once-daily will remain the dose for patients with KRAS <\/i>G12C-mutated NSCLC under accelerated approval.<\/p>\n

In May 2021<\/span>, LUMAKRAS was the first KRASG12C<\/sup> inhibitor to receive regulatory approval in the U.S., under accelerated approval. To date, over 15,000 patients worldwide have received LUMAKRAS\/LUMYKRAS through the clinical development program, early access and commercial use.<\/p>\n

About Advanced Non-Small Cell Lung Cancer and the KRAS <\/i>G12C Mutation
<\/b>Lung cancer is the leading cause of cancer-related deaths worldwide, and it accounts for more deaths worldwide than colon cancer, breast cancer and prostate cancer combined.1<\/sup><\/p>\n

KRAS<\/i> G12C is the most common KRAS<\/i> mutation in NSCLC.2<\/sup> About 13% of patients with non-squamous NSCLC harbor the KRAS<\/i> G12C mutation.3<\/sup> Unmet medical need remains high and treatment options are limited for NSCLC patients with the KRAS<\/i> G12C mutation whose first-line treatment has failed to work or has stopped working.<\/p>\n

LUMAKRAS\u00ae<\/sup><\/b> (sotorasib)<\/b> U.S.<\/b> Indication<\/b>
LUMAKRAS\u202fis indicated for the treatment of adult patients with\u202fKRAS<\/i> G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.<\/p>\n

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).<\/p>\n

LUMAKRAS\u00ae<\/sup> (sotorasib) Important U.S. Safety Information <\/b><\/p>\n

Hepatotoxicity <\/b><\/p>\n